CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
February 2019—Dragonfly Therapeutics has entered into a new agreement with Celgene to discover, develop, and commercialize immunotherapies for patients with solid and hematological cancers. The agreement builds on the companies’ 2017 four-target collaboration and increases the number of TriNKET (tri-specific NK cell engager therapies) immunotherapy drug candidates available to a total of eight. Dragonfly announced in mid-December that Celgene had licensed the first two drug candidates.
Pages: 1 2